The global blood transfusion diagnostics market is projected to grow to $8.67 billion by 2035, driven by automated testing and AI-driven blood safety solutions. This growth is expected to be fueled by increasing demand and rising prevalence of blood-related disorders, with the market expected to expand at a 6.5% compound annual growth rate (CAGR). The market was valued at $4.32 billion in 2020, indicating a significant increase in the demand for blood transfusion diagnostics.
What's Happening Right Now
The blood transfusion diagnostics market is experiencing a significant surge in growth, driven by the increasing adoption of automated testing systems and AI-driven blood safety solutions. The market is expected to be fueled by the rising prevalence of blood-related disorders, such as anemia and blood cancers, which require frequent blood transfusions. The global market is dominated by players such as Grifols SA (GRFS) and Immucor Inc., which are investing heavily in research and development to expand their product portfolios.
Why It Matters for US Investors
The growth of the blood transfusion diagnostics market has significant implications for US investors, particularly those invested in NYSE-listed stocks such as Grifols SA (GRFS) and Abbott Laboratories (ABT). The increasing demand for blood transfusion diagnostics is expected to drive revenue growth for these companies, with Grifols SA (GRFS) expected to grow at a 7.2% CAGR over the next five years. US investors can also consider investing in NASDAQ-listed stocks such as Exact Sciences Corporation (EXAS), which is a leading player in the molecular diagnostics market.
What Analysts Are Saying
Analysts are bullish on the growth prospects of the blood transfusion diagnostics market, with Goldman Sachs expecting the market to grow to $10.2 billion by 2030. Bank of America Merrill Lynch has also upgraded its rating on Grifols SA (GRFS) to buy, citing the company's strong growth prospects and increasing demand for its products. JPMorgan Chase has also initiated coverage on Immucor Inc. with a neutral rating, citing the company's strong product portfolio and increasing competition in the market.
Key Takeaways
- The global blood transfusion diagnostics market is projected to grow to $8.67 billion by 2035, driven by automated testing and AI-driven solutions.
- The market is expected to expand at a 6.5% compound annual growth rate (CAGR) over the next five years.
- US investors can consider investing in NYSE-listed stocks such as Grifols SA (GRFS) and Abbott Laboratories (ABT), as well as NASDAQ-listed stocks such as Exact Sciences Corporation (EXAS).
Frequently Asked Questions
What is driving the growth of the blood transfusion diagnostics market?
The growth of the blood transfusion diagnostics market is driven by the increasing adoption of automated testing systems and AI-driven blood safety solutions, as well as the rising prevalence of blood-related disorders.
Which companies are dominating the global blood transfusion diagnostics market?
The global market is dominated by players such as Grifols SA (GRFS) and Immucor Inc., which are investing heavily in research and development to expand their product portfolios.
What are the implications of the growth of the blood transfusion diagnostics market for US investors?
The growth of the blood transfusion diagnostics market has significant implications for US investors, particularly those invested in NYSE-listed stocks such as Grifols SA (GRFS) and Abbott Laboratories (ABT), as well as NASDAQ-listed stocks such as Exact Sciences Corporation (EXAS).
